Carlota Dobaño

ORCID: 0000-0002-6751-4060
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Malaria Research and Control
  • SARS-CoV-2 and COVID-19 Research
  • Mosquito-borne diseases and control
  • Complement system in diseases
  • COVID-19 Clinical Research Studies
  • vaccines and immunoinformatics approaches
  • HIV Research and Treatment
  • SARS-CoV-2 detection and testing
  • Parasites and Host Interactions
  • COVID-19 epidemiological studies
  • Long-Term Effects of COVID-19
  • COVID-19 Impact on Reproduction
  • Immunotherapy and Immune Responses
  • Research on Leishmaniasis Studies
  • Air Quality and Health Impacts
  • Immune responses and vaccinations
  • Pregnancy and preeclampsia studies
  • Vaccine Coverage and Hesitancy
  • Reproductive System and Pregnancy
  • Animal Virus Infections Studies
  • Travel-related health issues
  • Hepatitis B Virus Studies
  • Virology and Viral Diseases
  • Viral Infections and Outbreaks Research
  • Trypanosoma species research and implications

Universitat de Barcelona
2016-2025

Barcelona Institute for Global Health
2016-2025

Centro de Investigación en Red en Enfermedades Cardiovasculares
2022-2025

Instituto de Salud Carlos III
2020-2025

Departament de Salut
2024-2025

Manhiça Health Research Centre
2015-2024

Centro de Investigación Biomédica en Red
2021-2024

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
2024

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2011-2024

Hospital Clínic de Barcelona
2005-2024

Emma B. Hodcroft Moira Zuber Sarah Nadeau Timothy G. Vaughan Katharine H. D. Crawford and 95 more Christian L. Althaus Martina L. Reichmuth John E. Bowen Alexandra C. Walls Davide Corti Jesse D. Bloom David Veesler David Mateo Alberto Hernando Iñaki Comas Fernando Gónzález‐Candelas Fernando Gónzález‐Candelas Galo A. Goig Álvaro Chiner‐Oms Irving Cancino‐Muñoz Mariana G. López Manuela Torres‐Puente Inmaculada Gómez-Navarro Santiago Jiménez Lidia Ruiz-Roldán María Alma Bracho Neris García‐González Llúcia Martínez‐Priego Inmaculada Galán-Vendrell Paula Ruiz-Hueso Griselda De Marco Maria Loreto Ferrús Sandra Carbó-Ramírez Giuseppe D’Auria Mireia Coscollá Paula Ruiz-Rodríguez Francisco Javier Roig-Sena Isabel Sanmartín Daniel García‐Souto Ana Pequeño‐Valtierra José M. C. Tubío Jorge Rodríguez‐Castro Núria Rabella Ferrán Navarro Elisenda Miró Manuel Rodríguez‐Iglesias Fátima Galán‐Sánchez Salud Rodríguez-Pallares María de Toro María Pilar Bea-Escudero José Manuel Azcona Miriam Blasco Alberdi Alfredo Mayor Alberto L. García‐Basteiro Gemma Moncunill Carlota Dobaño Pau Cisteró Darı́o Garcı́a de Viedma Laura Pérez-Lago Marta Herránz Jon Sicilia Pilar Catalán-Alonso Patricia Muñóz Cristina Muñoz-Cuevas Guadalupe Rodríguez-Rodríguez Juan Alberola José Miguel Nogueira Juan J. Camarena Antonio Rezusta Alexander Tristancho-Baró Ana Milagro Nieves Felisa Martínez-Cameo Yolanda Gracia-Grataloup Elisa Martró Antoni E. Bordoy Anna Not Adrián Antuori-Torres Rafael Benito Sonia Algarate Jessica Bueno José Luís del Pozo José Antonio Boga Cristian Castelló-Abiétar Susana Rojo‐Alba Marta Elena Álvarez‐Argüelles Santiago Melón Maitane Aranzamendi-Zaldumbide Andrea Vergara-Gómez Jovita Fernández‐Pinero Miguel J. Martínez Jordi Vilà Elisa Rubio Aida Peiró-Mestres Jessica Navero‐Castillejos David Posada Diana Valverde Nuria Estévez‐Gómez Iria Fernández-Silva Loretta De Chiara Pilar Gallego‐García

10.1038/s41586-021-03677-y article EN other-oa Nature 2021-06-07

Abstract Health care workers (HCW) are a high-risk population to acquire SARS-CoV-2 infection from patients or other fellow HCW. This study aims at estimating the seroprevalence against in random sample of HCW large hospital Spain. Of 578 participants recruited 28 March 9 April 2020, 54 (9.3%, 95% CI: 7.1–12.0) were seropositive for IgM and/or IgG IgA SARS-CoV-2. The cumulative prevalence (presence antibodies past current positive rRT-PCR) was 11.2% (65/578, 8.8–14.1). Among those with...

10.1038/s41467-020-17318-x article EN cc-by Nature Communications 2020-07-08

The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial protective efficacy against clinical severe malaria disease in infants children. We investigated whether was specific to certain parasite genotypes at locus.We used polymerase chain reaction-based next-generation sequencing DNA extracted from samples 4985 participants survey polymorphisms. evaluated effect that polymorphic positions haplotypic regions within had on first episodes 1 year after...

10.1056/nejmoa1505819 article EN New England Journal of Medicine 2015-10-21

Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and individual characteristics influencing it, including impact pre-existing human coronaviruses causing common cold (HCoVs), is essential understand protective immunity COVID-19 devise effective surveillance strategies. IgM, IgA IgG levels against six antigens nucleocapsid antigen four HCoV (229E, NL63, OC43 HKU1) were quantified by Luminex, antibody neutralization capacity was assessed flow cytometry, in a cohort health care...

10.1038/s41467-021-24979-9 article EN cc-by Nature Communications 2021-08-06

The recent explosion in genomic sequencing has made available a wealth of data that can now be analyzed to identify protein antigens, potential targets for vaccine development. Here we present, the context Plasmodium falciparum , strategy rapidly identifies target antigens from large and complex genomes. Sixteen antigenic proteins recognized by volunteers immunized with radiation-attenuated P. sporozoites, but not mock controls, were identified. Several these more than previously identified...

10.1073/pnas.1633254100 article EN Proceedings of the National Academy of Sciences 2003-07-28

BackgroundCurrent recommendations to prevent malaria in African pregnant women rely on insecticide treated nets (ITNs) and intermittent preventive treatment (IPTp). However, there is no information the safety efficacy of their combined use.Methods1030 Mozambican all gravidities received a long-lasting ITN during antenatal clinic (ANC) visits and, irrespective HIV status, were enrolled randomised, double blind, placebo-controlled trial, assess 2-dose sulphadoxine-pyrimethamine (SP). The main...

10.1371/journal.pone.0001934 article EN cc-by PLoS ONE 2008-04-08

Background Maternal mortality is a major health problem concentrated in resource-poor regions. Accurate data on its causes using rigorous methods lacking, but essential to guide policy-makers and professionals reduce this intolerable burden. The aim of study was accurately describe the maternal death order contribute reduction, one regions world with highest ratios. Methods Findings We conducted prospective between October 2002 December 2004 tertiary-level referral hospital Maputo,...

10.1371/journal.pmed.0050044 article EN cc-by PLoS Medicine 2008-02-14

RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy African children and infants. In cohort of 1028 subjects from one low (Bagomoyo) two high (Nanoro, Kintampo) transmission sites, we analysed IgG plasma/serum concentration avidity to CSP (NANP-repeat C-terminal domains) after 3-dose vaccination against time clinical events during 12-months. Here report that induces substantial increases levels pre- post-vaccination (p < 0.001), higher NANP than C-terminus...

10.1038/s41467-019-10195-z article EN cc-by Nature Communications 2019-05-15

Abstract Background We performed a population-based study to describe the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on pregnancy outcomes. Methods This prospective, included pregnant women who consecutively presented at first/second trimester visits or delivery 3 hospitals in Barcelona, Spain. SARS-CoV-2 antibodies (immunoglobulin [Ig] G and IgM/IgA) were measured all participants, nasopharyngeal real-time polymerase chain reaction (RT-PCR) was...

10.1093/cid/ciab104 article EN other-oa Clinical Infectious Diseases 2021-02-05

COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) and questioning its utility seroprevalence studies. We investigated immunogenicity full-length shorter fragments N protein, HCoV. identified a C-terminus region SARS-CoV2 minimal sequence homology HCoV that was more specific for highly immunogenic. IgGs...

10.1016/j.trsl.2021.02.006 article EN other-oa Translational research 2021-02-15

Reliable serological tests are required to determine the prevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and characterize immunity disease in order address key knowledge gaps 2019 (COVID-19) pandemic. Quantitative suspension array technology (qSAT) assays based on xMAP Luminex platform overcome limitations rapid diagnostic enzyme-linked immunosorbent (ELISAs) with their higher precision, dynamic range, throughput, miniaturization,...

10.1128/jcm.01731-20 article EN Journal of Clinical Microbiology 2020-11-02

Background: Emerging evidence links ambient air pollution with coronavirus 2019 (COVID-19) disease, an association that is methodologically challenging to investigate. Objectives: We examined the between long-term exposure SARS-CoV-2 infection measured through antibody response, level of response among those infected, and COVID-19 disease. Methods: contacted 9,605 adult participants from a population-based cohort study in Catalonia June November 2020; most were 40 65 years age. drew blood...

10.1289/ehp9726 article EN public-domain Environmental Health Perspectives 2021-11-01

Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose needed to maximize effectiveness those previously exposed SARS-CoV-2 and what other factors affect responsiveness.We measured IgA, IgG IgM levels against spike (S) nucleocapsid (N) antigens from wild-type S Alpha, Beta Gamma variants concern, after BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) a cohort health care workers (N=578). Neutralizing...

10.1016/j.ebiom.2021.103805 article EN cc-by-nc-nd EBioMedicine 2022-01-01

Abstract Background Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host characteristics is likely reflected underlying SARS-CoV-2 antibody responses. Methods We measured IgM, IgA, IgG levels against spike nucleocapsid antigens 1076 adults a cohort study Catalonia between June November 2020 second time May July 2021. Questionnaire data electronic health records on vaccination testing were available both periods. Data several lifestyle, health-related,...

10.1186/s12916-022-02547-2 article EN cc-by BMC Medicine 2022-09-16

The emergence of new SARS-CoV-2 variants and the waning immunity raise concerns about vaccine effectiveness protection against COVID-19. While antibody response has been shown to correlate with risk infection original variant earlier concern, antibody-mediated Omicron factors associated remain uncertain.

10.1186/s12916-024-03304-3 article EN cc-by BMC Medicine 2024-03-07

There is an urgent need to deploy and develop new control tools that will reduce the intolerable burden of malaria. Intermittent preventive treatment in infants (IPTi) has potential become effective tool for malaria control.We performed a randomized, double-blind, placebo-controlled trial sulfadoxine-pyrimethamine (SP) 1503 Mozambican children. Doses SP or placebo were given at 3, 4, 9 months age. The intervention was administered alongside routine vaccinations delivered through Expanded...

10.1086/505431 article EN The Journal of Infectious Diseases 2006-07-05

Background The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against clinical for at least 21 months in a trial Mozambican children. Efficacy varied between different endpoints, such as parasitaemia or malaria; however the underlying mechanisms that determine efficacy and its duration remain unknown. We performed new, exploratory analysis explore differences of among participants better understand afforded by RTS,S. Methodology/Principal Findings study was Phase...

10.1371/journal.pone.0005165 article EN cc-by PLoS ONE 2009-04-13

Controlled human malaria infection (CHMI) by mosquito bite is a powerful tool for evaluation of vaccines and drugs against Plasmodium falciparum malaria. However, only small number research centres have the facilities required to perform such studies. CHMI needle syringe could help accelerate development anti-malaria interventions enabling worldwide employ CHMI. An open-label study was performed with aseptic, purified, cryopreserved P. sporozoites (PfSPZ Challenge) in 36 naïve volunteers. In...

10.1186/s12936-015-0817-x article EN cc-by Malaria Journal 2015-08-06

The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to evaluate comprehensively the immunogenicity of at peak response, factors affecting it, antibodies associated with clinical young children participating multicenter phase 3 trial for licensure.We measured total IgM, IgG, IgG1-4 subclass three constructs Plasmodium falciparum...

10.1186/s12916-018-1186-4 article EN cc-by BMC Medicine 2018-10-25
Coming Soon ...